WallStSmart

Cencora Inc. (COR)vsCosmos Health Inc. (COSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cencora Inc. generates 544743% more annual revenue ($325.78B vs $59.79M). COR leads profitability with a 0.5% profit margin vs -31.0%. COR earns a higher WallStSmart Score of 62/100 (C+).

COR

Buy

62

out of 100

Grade: C+

Growth: 6.7Profit: 6.0Value: 7.3Quality: 5.0

COSM

Hold

41

out of 100

Grade: D

Growth: 5.3Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: -2.37
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CORSignificantly Overvalued (-43.9%)

Margin of Safety

-43.9%

Fair Value

$254.20

Current Price

$325.08

$70.88 premium

UndervaluedFair: $254.20Overvalued

Intrinsic value data unavailable for COSM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COR3 strengths · Avg: 9.0/10
Return on EquityProfitability
133.5%10/10

Every $100 of equity generates 134 in profit

Market CapQuality
$63.59B9/10

Large-cap with strong market position

PEG RatioValuation
0.788/10

Growing faster than its price suggests

COSM2 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
37.9%10/10

Revenue surging 37.9% year-over-year

Areas to Watch

COR4 concerns · Avg: 3.0/10
P/E RatioValuation
39.2x4/10

Premium valuation, high expectations priced in

Profit MarginProfitability
0.5%3/10

0.5% margin — thin

Operating MarginProfitability
1.2%3/10

Operating margin of 1.2%

Price/BookValuation
33.1x2/10

Trading at 33.1x book value

COSM4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$16.65M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-63.8%2/10

ROE of -63.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : COR

The strongest argument for COR centers on Return on Equity, Market Cap, PEG Ratio. PEG of 0.78 suggests the stock is reasonably priced for its growth.

Bull Case : COSM

The strongest argument for COSM centers on Price/Book, Revenue Growth. Revenue growth of 37.9% demonstrates continued momentum.

Bear Case : COR

The primary concerns for COR are P/E Ratio, Profit Margin, Operating Margin. Thin 0.5% margins leave little buffer for downturns.

Bear Case : COSM

The primary concerns for COSM are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

COR profiles as a value stock while COSM is a hypergrowth play — different risk/reward profiles.

COSM carries more volatility with a beta of 4.47 — expect wider price swings.

COSM is growing revenue faster at 37.9% — sustainability is the question.

COSM generates stronger free cash flow (-4M), providing more financial flexibility.

Bottom Line

COR scores higher overall (62/100 vs 41/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cencora Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.

Cosmos Health Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Cosmos Holdings Inc. is a vertically integrated pharmaceutical company. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?